# Gilead Sciences **Source:** https://geo.sig.ai/brands/gilead-sciences **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** gilead.com **Last Updated:** 2026-04-14 ## Summary Antiviral biopharma with $28.6B FY2024 revenue; Biktarvy $14B HIV franchise; lenacapavir 99%+ HIV prevention efficacy in 2024 trials is landmark breakthrough; Trodelvy oncology expansion. ## Company Overview Gilead Sciences is a biopharmaceutical company specializing in antiviral medicines, oncology, and inflammatory diseases, founded in 1987 and headquartered in Foster City, California, trading on Nasdaq (GILD). The company reported approximately $28.6 billion in total revenues for FY2024 under CEO Daniel O'Day, driven by the world's leading HIV treatment franchise anchored by Biktarvy—the world's best-selling antiretroviral therapy with over $14 billion in annual global sales—along with Veklury (remdesivir) for COVID-19 treatment, and a growing oncology portfolio including Trodelvy (sacituzumab govitecan, an ADC for breast and bladder cancer), Yescarta, and Tecartus (CAR-T cell therapies). Gilead's 2024 HIV prevention breakthrough—lenacapavir, a twice-yearly injection preventing HIV infection with near-100% efficacy in large clinical trials—represents potentially the most important HIV prevention advance since the development of daily oral PrEP. The PURPOSE 1 and PURPOSE 2 clinical trials of lenacapavir (subcutaneous injection every 6 months) for HIV Pre-Exposure Prophylaxis demonstrated efficacy rates exceeding 99% in preventing HIV acquisition in high-risk populations—including cisgender women in sub-Saharan Africa and men who have sex with men globally—positioning lenacapavir as a transformative tool in global HIV elimination efforts. The World Health Organization's accelerated review and Gilead's commitment to generic licensing agreements for low-income countries signal lenacapavir's potential for broad global deployment. In oncology, Trodelvy's expansion into non-small cell lung cancer (NSFC), urothelial cancer, and HR+/HER2- metastatic breast cancer builds on its initial 2021 accelerated approval, while Yescarta competes with Bristol-Myers Squibb's Breyanzi in diffuse large B-cell lymphoma CAR-T therapy. In 2025-2026, Gilead faces HIV revenue pressure from long-acting treatment competition: ViiV Healthcare (GlaxoSmithKline-controlled) markets Cabenuva, a once-monthly injectable HIV treatment, and additional long-acting competitive options in development. Biktarvy faces eventual generic competition as composition-of-matter patents expire in the 2033-2036 timeframe. The oncology pipeline—TROP2 ADC Trodelvy, CAR-T therapies, and novel inflammatory disease assets—must become proportionally more significant as HIV growth moderates. Gilead's balance sheet, supported by strong HIV cash generation, enables continued M&A investment, following the $4.3 billion acquisition of CymaBay Therapeutics (primary biliary cholangitis) in 2024 and the $21 billion Immunomedics deal that brought Trodelvy. ## Frequently Asked Questions ### What does Gilead Sciences do? Gilead Sciences is a leading biopharmaceutical company that researches, develops, and commercializes innovative antiviral drugs for life-threatening infectious diseases. The company focuses primarily on treatments for HIV/AIDS, hepatitis B and C, influenza, and COVID-19, serving over 35 million patients globally across more than 100 countries. ### Who are Gilead Sciences' customers and target market? Gilead's customers include healthcare providers, hospitals, pharmacies, government health agencies, and patients with viral infections and certain cancers. The company serves a diverse global market including HIV patients requiring antiretroviral therapy, hepatitis patients seeking curative treatments, COVID-19 patients, and cancer patients through its Kite Pharma cell therapy division. ### When was Gilead Sciences founded? Gilead Sciences was founded in June 1987 under the original name Oligogen by Michael L. Riordan, MD, in Foster City, California. The company was renamed Gilead Sciences in 1988, went public on NASDAQ in 1992, and achieved its first full year of profitability in 2001—14 years after founding. ### Where is Gilead Sciences headquartered? Gilead Sciences is headquartered in Foster City, California, United States. The company operates globally with offices and research facilities across North America, Europe, Asia Pacific, and other regions, employing 17,600 people worldwide. In 2024, Gilead expanded by opening a new hub in Parsippany, New Jersey, as a center for innovation in oncology. ### How much revenue does Gilead Sciences generate? Gilead Sciences reported $28.8 billion in total revenue for full year 2024, representing a 6% increase from 2023. The company has a market capitalization of approximately $157 billion and generates trailing 12-month revenue of $28.9 billion as of 2025. ### What makes Gilead Sciences different from competitors? Gilead differentiates itself through its focused expertise in antiviral therapies, demonstrated by market-leading HIV and hepatitis C treatments, and its pioneering work in twice-yearly HIV prevention (lenacapavir). The company combines deep scientific innovation with strategic acquisitions totaling over $50 billion, including transformative deals like Pharmasset ($10.4B) and Kite Pharma ($11.9B), positioning it uniquely in both antivirals and cell therapy. ### Who are Gilead Sciences' main competitors? Gilead's main competitors include ViiV Healthcare and Merck in HIV treatments, AbbVie in hepatitis C, Pfizer and Merck in antivirals, and Bristol-Myers Squibb and Novartis in oncology and cell therapy. The competitive landscape varies by therapeutic area, with Gilead maintaining leadership positions in HIV and viral hepatitis. ### How can I contact Gilead Sciences? Gilead Sciences can be reached through their corporate headquarters in Foster City, California. For general inquiries, visit their official website at www.gilead.com. Patients seeking information about Gilead medications can contact Gilead's patient support programs, while healthcare professionals can reach out through dedicated medical information channels listed on the company website. ### Is Gilead Sciences hiring? Yes, Gilead Sciences actively recruits talent across research, clinical development, commercial, and corporate functions. With 17,600 employees globally, the company offers comprehensive benefits including competitive compensation, stock awards, immediate 401(k) vesting, up to 12 weeks parental leave, flexible work arrangements, and unique perks like winter and summer shutdowns. Career opportunities can be found at gilead.com/careers. ### What's the latest news about Gilead Sciences? Recent major developments include the June 2025 FDA approval of Yeztugo (lenacapavir) as the first twice-yearly HIV prevention option, the 2025 acquisition of Interius BioTherapeutics for $350 million to advance in vivo CAR-T therapies, and the August 2024 FDA approval of Livdelzi for primary biliary cholangitis. The company reported strong Q4 2024 financial results with 6% revenue growth to $28.8 billion. ### What is Gilead Sciences' market position? Gilead Sciences is a global leader in antiviral therapeutics with a commanding position in HIV treatment (Biktarvy) and hepatitis C (Sovaldi). As a member of the S&P 100 and Nasdaq-100 with a $157 billion market cap and Fortune 500 status since 2021, Gilead ranks among the top 10 biopharmaceutical companies globally, processing over 50 billion transactions annually for 35+ million patients across 100+ countries. ### What are Gilead Sciences' future plans? Gilead is focused on advancing its pipeline in HIV cure research, expanding cell therapy applications through Kite Pharma, developing novel treatments for autoimmune diseases through the MiroBio acquisition, and strengthening its oncology presence. The company plans to leverage its twice-yearly lenacapavir platform for both HIV treatment and prevention globally, while pursuing strategic acquisitions to enhance its therapeutic portfolio across liver disease, inflammation, and oncology. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*